SEC Form 4 · accession 0001140361-15-033293
Skye Bioscience, Inc. · SKYE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald W. McLaughlin
Director
Period of report
Aug 20, 2015
Accepted (ET)
Aug 24, 2015 · 8:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 20, 2015 | C | 31,250 | — | A | 31,250 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1 | — | Aug 20, 2015 | C | 10,000 | D | — | — | Common Stock | 31,250 | 0 | D |
Explanation of responses
- F1Shares of Series A Preferred Stock automatically converted into Common Stock on a 3.125-for-1 basis without payment of further consideration upon the closing of the Issuer's private offering on August 20, 2015, as reported in the Issuer's Form 8-K filed on August 21, 2015.